Abstract: Customers of a financial institution may apply for a line of credit for use with, e.g., a web-based bill pay service. The credit line may be determined using an average value of the customer's previously direct-deposited paychecks and an analysis of the customer's spending behavior using the web-based bill pay service. In some implementations, the financial institution may aggregate data points associated with the customer to make a determination of an amount, an interest rate, and a term of the line of credit. The line of credit may be used to pay bills from a financial services institution and unrelated third-party billers with which the customer has a payment history, as well as provide for cash for use by the customer.

Abstract: Disclosed are small molecules and pharmaceutical compositions comprising them that can be used in treating diseases associated with the major histocompatibility complex (MHC) molecule MR1.

Abstract: Customers of a financial institution may apply for a line of credit for use with, e.g., a web-based bill pay service. The credit line may be determined using an average value of the customer's previously direct-deposited paychecks and an analysis of the customer's spending behavior using the web-based bill pay service. In some implementations, the financial institution may aggregate data points associated with the customer to make a determination of an amount, an interest rate, and a term of the line of credit. The line of credit may be used to pay bills from a financial services institution and unrelated third-party billers with which the customer has a payment history, as well as provide for cash for use by the customer.

Abstract: Disclosed are small molecules and pharmaceutical compositions comprising them that can be used in treating diseases associated with the major histocompatibility complex (MHC) molecule MR1.

Abstract: There is provided a method for directly typing or sequencing HLA-A, -B, or -C alleles from a tissue sample wherein exons 2 and 3 of the HLA-A, -B, or -C alleles from the sample are amplified together in a locus specific manner and then separated out and individually amplified in a locus specific manner. After the two amplifications, the amplified exons are directly sequenced, the sequences are recombined, and a comparison is made between the derived HLA allele sequence and an HLA allele database, thereby giving an exact HLA-A, -B, or -C type for the sample being tested.

Abstract: The present invention relates generally to a methodology for the isolation, purification and identification of peptide ligands presented by MHC positive cells. In particular, the methodology of the present invention relates to the isolation, purification and identification of these peptide ligands from soluble class I and class 11 MHC molecules which may be from uninfected, infected, or tumorigenic cells. The methodology of the present invention broadly allows for these peptide ligands and their cognate source proteins thereof to be identified and used as markers for infected versus uninfected cells and/or tumorigenic versus nontumorigenic cells, with said identification being useful for marking or targeting a cell for therapeutic treatment or priming the immune response against infected cells.

Abstract: There is provided a method for directly typing or sequencing HLA class I or class II alleles from a tissue sample wherein at least one exon of the HLA class I or class II alleles from the sample is amplified in a locus specific manner utilizing two primers, wherein at least one of the primers has a universal or generic sequencing primer site incorporated therein. After amplification, the amplified exon(s) are directly sequenced, and a comparison is made between the derived HLA allele sequence and an HLA allele database, thereby giving an exact HLA type for the sample being tested.

Abstract: The present invention relates generally to a methodology for assaying the binding of a peptide to an individual, specific, soluble HLA molecule using fluorescence polarization. The peptides utilized in the method may be identified by indirect methods utilizing T lymphocytes, or by a direct method of epitope discovery described herein.

Abstract: The present invention relates generally to the production and use of functionally active soluble HLA molecules that are isolated and purified substantially away from other proteins, and methods of purifying same.

Abstract: A track drive system comprises a chassis frame and a drive wheel rotatably coupled to the chassis frame. An upper idler is rotatably coupled to the chassis frame rearwardly of the drive wheel. A forward idler is rotatably coupled to the chassis frame below the drive wheel. A suspended frame is pivotally coupled to the chassis frame by upper and lower swing arms. A rear idler is rotatably coupled to a rear portion of the suspended frame at a location displaced generally downwardly from an attachment point of the upper swing arm by a rear idler offset distance. A lower idler is rotatably coupled to a forward portion of the suspended frame. A biasing means biases the suspended frame away from the chassis frame.

Abstract: The field of the invention relates in general to at least one method and apparatus for the production of soluble MHC antigens and more particularly, but not by way of limitation, to at least one method and apparatus for the production of soluble Class I and II HLA molecules. The field of the invention also includes such produced soluble Class I and II HLA molecules and their use. According to the methodology of the present invention, the soluble Class I and II HLA molecules can be produced from either gDNA or cDNA starting material.

Abstract: The present invention relates generally to a methodology for assaying the binding of a peptide to an individual, specific, soluble HLA molecule. The peptides utilized in the method may be identified by indirect methods utilizing T lymphocytes, or by a direct method of epitope discovery described herein.

Abstract: An artificial antigen presenting cell includes a liposome having at least one recombinant soluble MHC-peptide complex incorporated therein. The artificial antigen presenting cell may also include at least one additional signal molecule incorporated therein for manipulating the intensity and quality of the immune response. The recombinant soluble MHC molecule is obtained by a method utilizing PCR amplification of gDNA or cDNA, and a tag is attached thereto for anchoring the recombinant soluble MHC molecule to the liposome.

Abstract: The field of the invention relates in general to at least one method and apparatus for the production of soluble MHC antigens and more particularly, but not by way of limitation, to at least one method and apparatus for the production of soluble Class I and II HLA molecules. The field of the invention also includes such produced soluble Class I and II HLA molecules and their use. According to the methodology of the present invention, the soluble Class I and II HLA molecules can be produced from either gDNA or cDNA starting material.

Abstract: The present invention relates generally to methods of directly or indirectly linking functionally active, individual soluble MHC complexes to one or more substrates such that the individual soluble MHC complexes maintain the physical, functional and antigenic integrity of a native MHC complex, as well as kits formed therefrom.

Abstract: The present invention relates generally to a methodology for the isolation, purification and identification of peptide ligands presented by MHC positive cells. In particular, the methodology of the present invention relates to the isolation, purification and identification of these peptide ligands from soluble class I and class II MHC molecules which may be from uninfected, infected, or tumorigenic cells. The methodology of the present invention broadly allows for these peptide ligands and their cognate source proteins thereof to be identified and used as markers for infected versus uninfected cells and/or tumorigenic versus nontumorigenic cells with said identification being useful for marking or targeting a cell for therapeutic treatment or priming the immune response against infected cells.

Abstract: The present invention generally relates to a MHC ligand database populated with MHC ligand sequences, motifs, extended motifs, submotifs, ligands unique to infected cells, tumor specific ligands, as well as a collection of current and future developed MHC ligand sequences developed by alternative methods. Other than the ligand sequences developed by alternative methods (which are in many cases non-standardized), the remaining ligand sequences are obtained in a standardized and minimum-variable dependent manner from soluble HLA molecules constructed according to the methodology described herein. The present invention further includes methodologies incorporating linear and predictive algorithm searching and comparison utilities.